259
Participants
Start Date
May 9, 2019
Primary Completion Date
April 24, 2020
Study Completion Date
May 9, 2020
evolocumab
Evolocumab will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive evolocumab (AMG 145) every 2 weeks or monthly subcutaneously.
placebo
Placebo will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive placebo every 2 weeks or monthly subcutaneously.
Peking University Third Hospital, Beijing
Beijing Hospital, Beijing
The Peoples Hospital of Liaoning Province, Shenyang
China-Japan Union Hospital of Jilin University, Changchun
The First Affiliated Hospital of Harbin Medical University, Harbin
Huashan Hospital Affiliated to Fudan University, Shanghai
Shanghai Yangpu District Central Hospital, Shanghai
Affiliated Hospital of Jiangsu University, Zhenjiang
Suzhou Kowloon Hospital, Suzhou
The Affiliated Hospital of Xuzhou Medical University, Xuzhou
Jinan Central Hospital, Jinan
Tianjin Medical University General Hospital, Tianjin
Tianjin Fourth Centre Hospital, Tianjin
Zhejiang Hospital, Hangzhou
Ningbo First Hospital, Ningbo
Taizhou Hospital of Zhejiang Province, Linhai
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
The Second Affiliated Hospital to Nanchang University, Nanchang
Changsha Central Hospital, Changsha
Xiangya Hospital Central South University, Changsha
The Second Xiangya Hospital of Central South University, Changsha
The Third Xiangya Hospital of Central South University, Changsha
Wuhan Puai Hospital, Wuhan
Guangdong Provincial Peoples Hospital, Guangzhou
Sun Yat-sen Memorial Hospital Sun Yat-sen University, Guangzhou
Guangzhou First Peoples  Hospital, Guangzhou
Guangzhou Red Cross Hospital, Guangzhou
Peking University Shenzhen Hospital, Shenzhen
The Second Nanning Peoples Hospital, Nanning
The First Affiliated Hospital of Xi An Jiao Tong University, Xi’an
Inner Mongolia Peoples Hospital, Hohhot
Lead Sponsor
Amgen
INDUSTRY